Advertisement

Long-Term Outcomes After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents or Coronary Artery Bypass Grafting for Multivessel Coronary Disease

Published:October 02, 2021DOI:https://doi.org/10.1016/j.amjcard.2021.08.047
      More evidence is required with respect to the comparative effectiveness of percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DESs) versus coronary artery bypass grafting (CABG) in contemporary clinical practice. This prospective observational registry–based study compared the outcomes of 6,647 patients with multivessel disease who underwent PCI with second-generation DES (n = 3,858) or CABG (n = 2,789) between January 2006 and June 2018 and for whom follow-up data were available for at least 2 to 13 years (median 4.8). The primary outcome was a composite of death, spontaneous myocardial infarction, or stroke. Baseline differences were adjusted using propensity scores and inverse probability weighting. In the overall cohort, there were no significant between-group differences in the adjusted risks for the primary composite outcome (hazard ratio [HR] for PCI vs CABG 1.03, 95% confidence interval [CI] 0.86 to 1.25, p = 0.73) and all-cause mortality (HR 0.95, 95% CI 0.76 to 1.20, p = 0.68). This relative treatment effect on the primary outcome was similar in patients with diabetes (HR 1.15, 95% CI 0.91 to 1.46, p = 0.25) and without diabetes (HR 0.95, 95% CI 0.73 to 1.22, p = 0.67) (p for interaction = 0.24). The adjusted risk of the primary outcome was significantly greater after PCI than after CABG in patients with left main involvement (HR 1.39, 95% CI 1.01 to 1.90, p = 0.044), but not in those without left main involvement (HR 0.94, 95% CI 0.76 to 1.16, p = 0.56) (p = 0.03 for interaction). In this prospective real-world long-term registry, we observed that the risk for the primary composite of death, spontaneous myocardial infarction, or stroke was similar between PCI with contemporary DES and CABG.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fihn SD
        • Blankenship JC
        • Alexander KP
        • Bittl JA
        • Byrne JG
        • Fletcher BJ
        • Fonarow GC
        • Lange RA
        • Levine GN
        • Maddox TM
        • Naidu SS
        • Ohman EM
        • Smith PK.
        2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
        J Am Coll Cardiol. 2014; 64: 1929-1949
        • Neumann FJ
        • Sousa-Uva M
        • Ahlsson A
        • Alfonso F
        • Banning AP
        • Benedetto U
        • Byrne RA
        • Collet JP
        • Falk V
        • Head SJ
        • Juni P
        • Kastrati A
        • Koller A
        • Kristensen SD
        • Niebauer J
        • Richter DJ
        • Seferović PM
        • Sibbing D
        • Stefanini GG
        • Windecker S
        • Yadav R
        • Zembala MO
        2018 ESC/EACTS Guidelines on myocardial revascularization.
        Kardiol Pol. 2018; 76: 1585-1664
        • Lee PH
        • Ahn JM
        • Chang M
        • Baek S
        • Yoon SH
        • Kang SJ
        • Lee SW
        • Kim YH
        • Lee CW
        • Park SW
        • Park DW
        • Park SJ.
        Left main coronary artery disease: secular trends in patient characteristics, treatments, and outcomes.
        J Am Coll Cardiol. 2016; 68: 1233-1246
        • Bangalore S
        • Guo Y
        • Samadashvili Z
        • Blecker S
        • Xu J
        • Hannan EL.
        Everolimus-eluting stents or bypass surgery for multivessel coronary disease.
        N Engl J Med. 2015; 372: 1213-1222
        • Park DW
        • Yun SC
        • Lee SW
        • Kim YH
        • Lee CW
        • Hong MK
        • Kim JJ
        • Choo SJ
        • Song H
        • Chung CH
        • Lee JW
        • Park SW
        • Park SJ.
        Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary artery disease.
        Circulation. 2008; 117: 2079-2086
        • Park DW
        • Kim YH
        • Song HG
        • Ahn JM
        • Oh J
        • Kim WJ
        • Lee JY
        • Kang SJ
        • Lee SW
        • Lee CW
        • Park SW
        • Yun SC
        • Jung SH
        • Choo SJ
        • Chung CH
        • Lee JW
        • Park SJ.
        Long-term comparison of drug-eluting stents and coronary artery bypass grafting for multivessel coronary revascularization: 5-year outcomes from the Asan Medical Center-Multivessel Revascularization Registry.
        J Am Coll Cardiol. 2011; 57: 128-137
        • Garcia-Garcia HM
        • McFadden EP
        • Farb A
        • Mehran R
        • Stone GW
        • Spertus J
        • Onuma Y
        • Morel MA
        • van Es GA
        • Zuckerman B
        • Fearon WF
        • Taggart D
        • Kappetein AP
        • Krucoff MW
        • Vranckx P
        • Windecker S
        • Cutlip D
        • Serruys PW
        Academic Research Consortium. Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document.
        Circulation. 2018; 137: 2635-2650
        • Gregson J
        • Stone GW
        • Ben-Yehuda O
        • Redfors B
        • Kandzari DE
        • Morice MC
        • Leon MB
        • Kosmidou I
        • Lembo NJ
        • Brown 3rd, WM
        • Karmpaliotis D
        • Banning AP
        • Pomar J
        • Sabaté M
        • Simonton CA
        • Dressler O
        • Kappetein AP
        • Sabik 3rd, JF
        • Serruys PW
        • Pocock SJ.
        Implications of alternative definitions of peri-procedural myocardial infarction after coronary revascularization.
        J Am Coll Cardiol. 2020; 76: 1609-1621
        • Rosenbaum PR
        • Rubin DB.
        The central role of the propensity score in observational studies for causal effects.
        Biometrika. 1983; 70: 41-55
        • D'Agostino Jr., RB
        Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.
        Stat Med. 1998; 17: 2265-2281
        • Park DW
        • Ahn JM
        • Yun SC
        • Yoon YH
        • Kang DY
        • Lee PH
        • Lee SW
        • Park SW
        • Seung KB
        • Gwon HC
        • Jeong MH
        • Jang Y
        • Kim HS
        • Seong IW
        • Park HS
        • Ahn T
        • IH Chae
        • Tahk SJ
        • Park SJ.
        10-year outcomes of stents versus coronary artery bypass grafting for left main coronary artery disease.
        J Am Coll Cardiol. 2018; 72: 2813-2822
        • Park SJ
        • Ahn JM
        • Kim YH
        • Park DW
        • Yun SC
        • Lee JY
        • Kang SJ
        • Lee SW
        • Lee CW
        • Park SW
        • Choo SJ
        • Chung CH
        • Lee JW
        • Cohen DJ
        • Yeung AC
        • Hur SH
        • Seung KB
        • Ahn TH
        • Kwon HM
        • Lim DS
        • Rha SW
        • Jeong MH
        • Lee BK
        • Tresukosol D
        • Fu GS
        • Ong TK
        • BEST Trial Investigators
        Trial of everolimus-eluting stents or bypass surgery for coronary disease.
        N Engl J Med. 2015; 372: 1204-1212
        • Thuijs DJFM
        • Kappetein AP
        • Serruys PW
        • Mohr FW
        • Morice MC
        • Mack MJ
        • Holmes Jr, DR
        • Curzen N
        • Davierwala P
        • Noack T
        • Milojevic M
        • Dawkins KD
        • da Costa BR
        • Jüni P
        • Head SJ
        SYNTAX Extended Survival Investigators. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial [published correction appears in Lancet 2020;395:870].
        Lancet. 2019; 394: 1325-1334
        • Stone GW
        • Kappetein AP
        • Sabik JF
        • Pocock SJ
        • Morice MC
        • Puskas J
        • Kandzari DE
        • Karmpaliotis D
        • Brown 3rd, WM
        • Lembo NJ
        • Banning A
        • Merkely B
        • Horkay F
        • Boonstra PW
        • van Boven AJ
        • Ungi I
        • Bogáts G
        • Mansour S
        • Noiseux N
        • Sabaté M
        • Pomar J
        • Hickey M
        • Gershlick A
        • Buszman PE
        • Bochenek A
        • Schampaert E
        • Pagé P
        • Modolo R
        • Gregson J
        • Simonton CA
        • Mehran R
        • Kosmidou I
        • Généreux P
        • Crowley A
        • Dressler O
        • Serruys PW
        • EXCEL Trial Investigators
        Five-year outcomes after PCI or CABG for left main coronary disease [published correction appears in N Engl J Med 2020;382:1078].
        N Engl J Med. 2019; 381: 1820-1830
        • Holm NR
        • Mäkikallio T
        • Lindsay MM
        • Spence MS
        • Erglis A
        • Menown IBA
        • Trovik T
        • Kellerth T
        • Kalinauskas G
        • Mogensen LJH
        • Nielsen PH
        • Niemelä M
        • Lassen JF
        • Oldroyd K
        • Berg G
        • Stradins P
        • Walsh SJ
        • Graham ANJ
        • Endresen PC
        • Fröbert O
        • Trivedi U
        • Anttila V
        • Hildick-Smith D
        • Thuesen L
        • Christiansen EH
        • NOBLE investigators
        Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.
        Lancet. 2020; 395: 191-199
        • Park DW
        • Ahn JM
        • Park H
        • Yun SC
        • Kang DY
        • Lee PH
        • Kim YH
        • Lim DS
        • Rha SW
        • Park GM
        • Gwon HC
        • Kim HS
        • Chae IH
        • Jang Y
        • Jeong MH
        • Tahk SJ
        • Seung KB
        • Park SJ
        • PRECOMBAT Investigators
        Ten-year outcomes after drug-eluting stents versus coronary artery bypass grafting for left main coronary disease: extended follow-up of the PRECOMBAT trial.
        Circulation. 2020; 141: 1437-1446
        • Farkouh ME
        • Domanski M
        • Sleeper LA
        • Siami FS
        • Dangas G
        • Mack M
        • Yang M
        • Cohen DJ
        • Rosenberg Y
        • Solomon SD
        • Desai AS
        • Gersh BJ
        • Magnuson EA
        • Lansky A
        • Boineau R
        • Weinberger J
        • Ramanathan K
        • Sousa JE
        • Rankin J
        • Bhargava B
        • Buse J
        • Hueb W
        • Smith CR
        • Muratov V
        • Bansilal S
        • King 3rd, S
        • Bertrand M
        • Fuster V
        • FREEDOM Trial Investigators
        Strategies for multivessel revascularization in patients with diabetes.
        N Engl J Med. 2012; 367: 2375-2384
        • Tam DY
        • Dharma C
        • Rocha R
        • Farkouh ME
        • Abdel-Qadir H
        • Sun LY
        • Wijeysundera HC
        • Austin PC
        • Udell JA
        • Gaudino M
        • Fremes SE
        • Lee DS.
        Long-term survival after surgical or percutaneous revascularization in patients with diabetes and multivessel coronary disease.
        J Am Coll Cardiol. 2020; 76: 1153-1164
        • Head SJ
        • Milojevic M
        • Taggart DP
        • Puskas JD.
        Current practice of state-of-the-art surgical coronary revascularization.
        Circulation. 2017; 136: 1331-1345
        • Bhatt DL.
        CABG the clear choice for patients with diabetes and multivessel disease.
        Lancet. 2018; 391: 913-914
        • Farkouh ME
        • Domanski M
        • Dangas GD
        • Godoy LC
        • Mack MJ
        • Siami FS
        • Hamza TH
        • Shah B
        • Stefanini GG
        • Sidhu MS
        • Tanguay JF
        • Ramanathan K
        • Sharma SK
        • French J
        • Hueb W
        • Cohen DJ
        • Fuster V
        FREEDOM Follow-On Study Investigators. Long-term survival following multivessel revascularization in patients with diabetes: the FREEDOM follow-on study.
        J Am Coll Cardiol. 2019; 73: 629-638
        • Head SJ
        • Milojevic M
        • Daemen J
        • Ahn JM
        • Boersma E
        • Christiansen EH
        • Domanski MJ
        • Farkouh ME
        • Flather M
        • Fuster V
        • Hlatky MA
        • Holm NR
        • Hueb WA
        • Kamalesh M
        • Kim YH
        • Mäkikallio T
        • Mohr FW
        • Papageorgiou G
        • Park SJ
        • Rodriguez AE
        • Sabik 3rd, JF
        • Stables RH
        • Stone GW
        • Serruys PW
        • Kappetein AP.
        Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
        Lancet. 2018; 391: 939-948
        • Park SJ
        • Park DW.
        Diabetes in myocardial revascularization for left main coronary artery disease: predictor or decision maker?.
        J Am Coll Cardiol. 2019; 73: 1629-1632
        • SoS Investigators
        Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial.
        Lancet. 2002; 360: 965-970
        • Zelniker TA
        • Wiviott SD
        • Raz I
        • Im K
        • Goodrich EL
        • Bonaca MP
        • Mosenzon O
        • Kato ET
        • Cahn A
        • Furtado RHM
        • Bhatt DL
        • Leiter LA
        • McGuire DK
        • Wilding JPH
        • Sabatine MS.
        SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [published correction appears in Lancet 2019;393:30].
        Lancet. 2019; 393: 31-39
        • Pereira AC
        • Lopes NH
        • Soares PR
        • Krieger JE
        • de Oliveira SA
        • Cesar LA
        • Ramires JA
        • Hueb W.
        Clinical judgment and treatment options in stable multivessel coronary artery disease: results from the one-year follow-up of the MASS II (Medicine, Angioplasty, or Surgery Study II).
        J Am Coll Cardiol. 2006; 48: 948-953